Curis, Inc. (Curis) is engaged in the research and development of innovative cancer therapeutics. The Company conducts its research and development programs both internally and through strategic collaborations. Its drug cancidate, Erivedge, which is approved medicine for the treatment of advanced basal cell carcinoma (BCC), is commercialized by F. Hoffmann-La Roche Ltd (Roche) and Genentech Inc., (Genentech), a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis’s development programs include both internal and under collaboration. The Company’s drug candidates include Dual histone deacetylas (HDAC) and phosphatidylinositol-3-kinase (PI3K) Inhibitor, which is CUDC-907; an antagonist of inhibitor of apoptosis (IAP) proteins, which is CUDC-427; Hedgehog Pathway Inhibitors, which include Erivedge, and HSP90 Inhibitor, which include Debio 0932.